This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Abbvie Inc.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Steve St Gallay: Innovator in Pharmaceutical Research
Introduction
Steve St Gallay is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target specific medical conditions. His work has the potential to impact the treatment of various diseases, showcasing his dedication to innovation in healthcare.
Latest Patents
Steve St Gallay holds a patent for Nicotinamide RIPK1 inhibitors. This patent includes compounds of Formula (I) and pharmaceutically acceptable salts that are useful as RIPK1 inhibitors. The patent also details pharmaceutical compositions comprising these compounds, as well as methods of use and preparation. Furthermore, it provides methods for treating Ulcerative Colitis using a compound of Formula (I). This innovative approach highlights his commitment to advancing medical treatments.
Career Highlights
Throughout his career, Steve has worked with AbbVie Inc., a leading global biopharmaceutical company. His role at AbbVie has allowed him to collaborate with other talented professionals in the field, contributing to groundbreaking research and development.
Collaborations
Steve has collaborated with notable coworkers, including James Patrick Stambuli and Maria A Argiriadi. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the quality of their research.
Conclusion
Steve St Gallay's contributions to pharmaceutical research, particularly through his patent on Nicotinamide RIPK1 inhibitors, demonstrate his innovative spirit and commitment to improving healthcare. His work continues to inspire advancements in the treatment of medical conditions, making a lasting impact in the field.